RENB (Renovaro) Days Sales Outstanding : 0.00 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Renovaro Days Sales Outstanding?

Renovaro's average Accounts Receivable for the three months ended in Dec. 2024 was $0.00 Mil. Renovaro's Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Renovaro's Days Sales Outstanding or its related term are showing as below:

RENB's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 71.28
* Ranked among companies with meaningful Days Sales Outstanding only.

Renovaro's Days Sales Outstanding stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Renovaro Days Sales Outstanding Historical Data

The historical data trend for Renovaro's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Days Sales Outstanding Chart

Renovaro Annual Data

Trend

Dec14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Days Sales Outstanding

Get a 7-Day Free Trial

Renovaro Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Renovaro's Days Sales Outstanding

For the Biotechnology subindustry, Renovaro's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renovaro's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Renovaro's Days Sales Outstanding falls into.

Renovaro Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Renovaro's Days Sales Outstanding for the fiscal year that ended in Jun. 2024 is calculated as

	Days Sales Outstanding (A: Jun. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Jun. 2024 ))	/	count )	/	Revenue (A: Jun. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Renovaro's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding (Q: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2024 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Renovaro (NAS:RENB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Renovaro Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Renovaro's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

2Q5:Germany

Address

2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067

Website

https://www.renovarogroup.com

Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.

Executives

Anderson Wittekind William	10 percent owner	8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leni Boeren	director	2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks	director	CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard	10 percent owner	VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette	officer: Executive Vice President	2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu	10 percent owner	2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev	director, 10 percent owner	FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler	other: Former director see note below	330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol	director	606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen	director	STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche	officer: Chief Financial Officer	318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne	director	NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Leire, Eric Jean Marie	director, officer: CEO; President	C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060